期刊文献+

脂质体-c-raf-1反义寡核苷酸转染对人卵巢癌裸鼠皮下移植瘤形成的作用

Effects of Liposome-c-raf-1 Antisense Oligodeoxynucleotides Transfection on the Human Ovarian Cancer Transplanted Subcutaneously in Nude Mice
下载PDF
导出
摘要 目的 探讨经脂质体一硫代磷酸化修饰的c raf 1反义寡脱氧核苷酸(ASODN)作用后的卵巢上皮癌细胞株SKOV3在裸鼠皮下的成瘤能力。方法 利用脂质体将经硫代磷酸化修饰的寡核苷酸导入SKOV3细胞,然后将这种被转染的细胞接种于裸鼠皮下,观察肿瘤体积的变化,并计算抑瘤率。结果 经脂质体c raf 1 ASODN作用后的卵巢上皮癌细胞在裸鼠皮下成瘤能力降低,最大抑瘤率达35.3%(P<0.05)。首次出现肉眼可见肿瘤的平均时间延长为8.8天(P <0.05)。结论 c raf 1 癌基因的反义调控能降低卵巢上皮癌细胞的成瘤能力,抑制肿瘤生长,在卵巢上皮癌的基因治疗中有一定作用。 Objective To investigate the effects of liposome c raf 1 antisense phosphorothioate oligodeoxynucleotides (c raf 1 ASODN) on the human ovarian epithelial cancer transplanted subcutaneously in nude mice.Methods Human ovarian epithelial cancer cell lines SKOV 3 were treated with liposome c raf 1 ASODN, then transplanted subcutaneously in nude mice. The Changes of tumor volume were observed and the tumor growth inhibitory rate was calculated.Results The tumorigenic ability of the treated cell lines was reduced, the maximum tumor growth inhibitory rate was 35.3% ( P < 0.05 ). The first time that tumor can be detected was increased up to 8.8 days ( P < 0.05 ).Conclusion The results suggested that c raf 1 ASODN transfection can inhibit the tumorigenesis of ovarian epithelial cancer cell lines in nude mice, it may be a useful gene therapy for the ovarian epithelial carcinoma.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2005年第3期149-151,共3页 Cancer Research on Prevention and Treatment
关键词 C-RAF-1 反义寡核苷酸 人卵巢上皮癌 裸鼠皮下移植瘤 c-raf-1 Antisense oligodeoxynucleotide Human ovarian epithelial cancer Tumor transplanted subcutaneously in nude mice
  • 相关文献

参考文献8

  • 1徐丛剑,金志军,丰有吉,姚明,张惜阴,尹德领,许秀兰,顾健人.人卵巢癌裸鼠腹腔及网膜移植的研究[J].现代妇产科进展,1997,6(2):111-113. 被引量:2
  • 2Guha C,Guha U,Tribius S,et al. Antisense ATM gene therapy:a strategy to increase the radiosensitivity of human tumors[J].Gene Ther,2000,7(10):852-858.
  • 3Pietras K, Ostman A, Sjoquist M, et al. Inhibition of platelet-derived Growth Factor Receptor reduces interstitial hypertension and increase transcapillary transport in tumor[J].Cancer Res,2001,61(7):2929-2934.
  • 4Hung WC,Hung JS,Chuang LY. Antisense oligodeoxynucltotides targeted against different regions of cyclin D mRNA may exert different inhibitory effects on cell growth and gene expression[J]. Biochem Biophys Res commun,1996,220(9):719-721.
  • 5Skiuing JS,squatrito RC,Connor JP, et al. P53 gene mutation analysis and antisense-mediated growth inhibition of human overian carcinoma cell lines[J]. Gynecol Oncol,1996,60(1):72-77.
  • 6O'Dwyer PJ, Stevenson JP, Gallagher M, et al. C-raf-1 depletion and tumor responses in patient treated with the c-raf-1 antisense oligodeoxynucleotide IsIs 5132(CGP 68936 A)[J].Clinical Cancer Research,1999,5(12):3977-3982.
  • 7O'Dwyer PJ, Gallagher M. Phase I Clinical/pharmacokinetic and pharma -codynamic trial of the c-raf-1 antisense oligonucleotideIsIs 5132 (CGP 69846 A)[J]. J Clin Oncol, 1999, 17(7): 2227-2236.
  • 8Marcusson EG, yacyshyn BR, Shanahan WJ, et al. Preclinical and clinical pharmacolgy of antisense oligonucleotides[J]. Mol Biotechnol,1999,12(1):1-11.

共引文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部